AB Science S.A. (ABSCF) Research

AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors, designed for applications in both human and animal medicine. The company's flagship product is masitinib, a tyrosine kinase inhibitor currently undergoing extensive Phase III clinical trials for a diverse range of serious conditions. These include prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II trials for the treatment of Covid-19. Beyond masitinib, AB Science is advancing other therapeutic candidates, such as AB8939, a synthetic microtubule destabilizer intended for acute myeloid leukemia. Another compound, AB20001, is in Phase II investigation, assessing the safety and efficacy of masitinib combined with isoquercetin for hospitalized patients suffering from moderate to severe COVID-19. In Europe, masitinib is already commercially available for certain indications under the brand name Masivet. Established in 2001, AB Science S.A. maintains its corporate headquarters in Paris, France.

Open AB Science S.A. (ABSCF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.